Frédérique Rousseau

Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion.

Jean Marc Extra, Frédérique Rousseau, René Bruno et al. · PubMed · 1993 · 253 citations

Chemoprevention Strategy, Pharmacokinetic Study, Pharmacotherapy +21

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet · 2019 · 125 citations

Breast Oncology, Oncology, Early Breast Cancer +6

Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer

Claire Falandry, Frédérique Rousseau, Marie‐Ange Mouret‐Reynier et al. · JAMA Oncology · 2021 · 78 citations · Full text

Multidisciplinary development of the Geriatric Core Dataset for clinical research in older patients with cancer: A French initiative with international survey

Éléna Paillaud, Pierre Soubeyran, Philippe Caillet et al. · European Journal of Cancer · 2018 · 68 citations

Geriatric Oncology, Geriatric Core Dataset, Aging +11

Frailty Markers and Treatment Decisions in Patients Seen in Oncogeriatric Clinics: Results from the ASRO Pilot Study

Anaïs Farcet, Laure de Decker, Vanessa Pauly et al. · PLoS ONE · 2016 · 61 citations · Full text